SAB Biotherapeutics announces public stock offering; shares down [Seeking Alpha]
SAB Biotherapeutics, Inc. (SABS)
Company Research
Source: Seeking Alpha
The offering includes an option for underwriters to buy up to 15% additional securities within 30 days. All securities in the offering will be sold directly by the company. Proceeds will primarily support development of its lead candidate SAB-142 for Type 1 Diabetes. Funds will also cover clinical trials, manufacturing, regulatory activities, and general corporate expenses. SABS shares down 6.9% post-market. Fresh Stock Ideas, Every Day Explore diverse investing perspectives with daily analysis from experts across the market. Subscribe to Stock Ideas Sign Up More on SAB Biotherapeutics SAB Biotherapeutics reports FY results Seeking Alpha's Quant Rating on SAB Biotherapeutics Historical earnings data for SAB Biotherapeutics Financial information for SAB Biotherapeutics Recommended For You More Trending News
Show less
Read more
Impact Snapshot
Event Time:
SABS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SABS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SABS alerts
High impacting SAB Biotherapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
SABS
News
- SAB BIO Announces Closing of $85 Million Public Offering of Common Stock and Pre-Funded Warrants [Yahoo! Finance]Yahoo! Finance
- SAB BIO Announces Closing of $85 Million Public Offering of Common Stock and Pre-Funded WarrantsGlobeNewswire
- SAB BIO Announces Pricing of $85 Million Public Offering of Common Stock and Pre-Funded WarrantsGlobeNewswire
- SAB BIO Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants [Yahoo! Finance]Yahoo! Finance
- SAB BIO Announces Proposed Public Offering of Common Stock and Pre-Funded WarrantsGlobeNewswire
SABS
Sec Filings
- 3/19/26 - Form 8-K
- 3/19/26 - Form 424B5
- 3/17/26 - Form 424B5
- SABS's page on the SEC website